Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Darolutamide DDI Study with CYP3A4 and P-gp Substrates
NCT03237416Phase 1Completed
- Sponsor
- Bayer
- Start
- Aug 2017
- Primary completion
- Oct 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of darolutamide in prostate cancer (PCa), sponsored by Bayer. Primary endpoints: AUC in plasma of non-conjugated dabigatran (AUC(0-tlast)), C(max) in plasma of non-conjugated dabigatran and 2 more. Started Aug 2017; status: completed.
02
Drugs
darolutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03237416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03237416.